SEARCH · PubMed Health

Results for “POTASSIUM IODIDE”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 73 records · Page 4Linked to original sources

PubMed1979

[Alteration of TSH secretion in children with goitre after short-term treatment with potassium iodide (author's transl)].

300 microgram of potassium iodide daily were administered over a period of two weeks to 12 children with goitre. Basal TSH concentrations, maximal TSH increase after TRH and integrated TSH secretion after TRH were significantly decreased in this group whereas the increase of total thyroxine (T4-RIA) did not reach significance. It appears that in the development of iodine deficiency goitre in children a sensitive feed-back system is predominant. Early administration of iodine or even better general iodinated salt prophylaxis seem to be the pathogenetically correct approach in solving the common goitre problem.

Adolescent↗

PubMed1975

Thyroid failure after potassium iodide treatment of diffuse toxic goiter.

1. The treatment of Graves' Disease by Potassium Iodide (like thyroidectomy, radioiodine, and antithyroid drugs) is followed by rate failure of thyroid function. 2. These findings suggest that the natural history of Graves' Disease may be one of progression from hyperthyroidism towards a decreased thyroid functional state. This progression may be accelerated by ablative methods of treatment. 3. Certainly, all patients with Graves' Disease, no matter what the treatment may be, should be followed carefully for the rest of their lives. 4. In certain patients, Potassium Iodide appears to be an effective means of controlling the hyperthyroidism of Graves' Disease.

Adult↗

PubMed1987

Granulomatous vasculitis as a complication of potassium iodide treatment for Sweet's syndrome.

A case of Sweet's syndrome treated with potassium iodide is hereby described. The patient responded well a few days after the initiation of therapy, but the evolution was complicated with a severe clinical deterioration two weeks later. Systemic vasculitis was diagnosed on the basis of significant impairment of renal function, involvement of the eyes (papillitis) and the skin biopsy which showed a leukocytoclastic vasculitis. This systemic vasculitis was attributed to the potassium iodide therapy.

Adult↗

PubMed1990

The effect of pre-operative potassium iodide therapy on antibody production.

Previous studies have suggested that iodide may increase the incidence of thyroid disease and anti-thyroid antibodies in predisposed individuals. This study has considered the effects of pre-operative potassium iodide (60 mg twice daily, for 10 days) on the immune system of patients with Graves' disease. The treatment regimen used maintained all patients in a clinically and biochemically euthyroid state prior to surgery. Potassium iodide significantly increased serum thyrotropin receptor antibody levels and B cell activity as determined by increased immunoglobulin production from mitogen stimulated peripheral blood lymphocytes. These effects were not observed in the two control groups of Graves' disease patients. Our in vivo findings would support previous in vitro work showing that potassium iodide does act on the immune system and this may be the mechanism by which iodide induces thyroid dysfunction in predisposed individuals.

Antibody Formation↗

PubMed1998

Intermittent oral administration of potassium iodide solution for the correction of iodine deficiency.

Iodized salt and iodized oil are the main methods used to prevent iodine deficiency, but sometimes alternative approaches are needed. We tested the efficacy of various regimens for the intermittent administration of potassium iodide in Hwedza, Zimbabwe, an area of known severe iodine deficiency. We divided 304 schoolchildren aged 7-13 y into five equal groups that received iodine as a 10% solution of potassium iodide as follows: 8.7 mg every 2 wk (group A), 29.7 mg every month (group B), 148.2 mg every 3 mo (group C), 382 mg every 6 mo (group D), or 993 mg once (group E). The follow-up period was 13 mo. No adverse effects were encountered with any of these doses. After 6 mo, the median blood spot thyroglobulin concentration had decreased in all groups and had normalized in groups A and B to values found in iodine-sufficient populations. The number of children with elevated thyroid-stimulating hormone concentrations decreased in groups A-C, but the changes were not significant. Urine iodine concentration generally remained low in all groups but increased in group A. After 13 mo, mean thyroid volume measured by ultrasound had decreased in groups A and B to values comparable with those in iodine-sufficient areas, and was unchanged in the other groups. We conclude that oral potassium iodide is effective for the prophylaxis of iodine deficiency if given as a dose of 30 mg I monthly or 8 mg biweekly.

Administration, Oral↗

PubMed1998

Induction of squamous cell carcinomas in the salivary glands of rats by potassium iodide.

In a 2-year carcinogenicity study of potassium iodide (KI) in F344/DuCrj rats, squamous cell carcinomas (SCCs) were observed in the salivary glands of 4/40 males and 3/40 females receiving 1000 ppm KI in the drinking water. Ductular proliferation with lobular atrophy was observed at high incidence in the submandibular glands of the high-dose animals, and squamous metaplasia was frequently evident within the proliferative ductules and the larger interlobular ducts. A transition from metaplasia to SCC was apparent. The results suggest that squamous metaplasia in proliferative ductules, occurring secondarily to lobular impairment induced by KI, may develop into SCCs via a non-genotoxic, proliferation-dependent mechanism.

Administration, Oral↗

PubMed1982

Effects of potassium iodide, colchicine and dapsone on the generation of polymorphonuclear leukocyte-derived oxygen intermediates.

The effects of potassium iodide, colchicine and dapsone on the in vitro generation of polymorphonuclear leukocyte (PMN)-derived oxygen intermediates were investigated. These three drugs have beneficial effects on those conditions in which PMNs play an important pathogenetic role. Three oxygen intermediates, superoxide anion (O2-), hydrogen peroxide (H2O2), hydroxyl radical (OH.) and chemiluminescence were included in assay studies. Dose response studies were performed with therapeutic doses of the drugs (10 microM--mM). We found that both potassium iodide and dapsone significantly suppressed the generation of oxygen intermediates, except for O2-. Colchicine decreased OH. production. Our results show tha these agents to some extent exert their anti-inflammatory effects by interfering with the PMN-dependent production of oxygen intermediates, thus conferring protection from auto-oxidative tissue injury. This may account for their clinical efficacy in many PMN-mediated dermatological diseases.

Anions↗

PubMed1980

Treatment of acute febrile neutrophilic dermatosis (Sweet's Syndrome) with potassium iodide.

6 cases with acute febrile neutrophilic dermatosis (Sweet's syndrome) responded rapidly and dramatically to treatment with potassium iodide. All patients became afebrile and symptom-free within 24--48 h after therapy. The cutaneous eruptions subsided completely in 3--5 days. 5 of the patients received the drug only for 2 weeks, but they have had no recurrences. Although the remaining 1 patient had shown minor recurrences after cessation of the medication, he was free of all symptoms during the therapy. The mode of the action of potassium iodide is also discussed.

Adult↗

PubMed1976

Treatment of erythema nodosum and nodular vasculitis with potassium iodide.

Twenty-four of twenty-eight patients with erythema nodosum and sixteen of seventeen patients with nodular vasculitis responded to treatment with potassium iodide. Relief of symptoms occurred within 2 days. The average duration of treatment was 3 weeks and the lesions took an average of 2 weeks to resolve. The possible mode of action of potassium iodide is discussed and an immunosuppressive effect mediated by heparin is suggested.

Adolescent↗

PubMed1988

Iodine supplementation: comparison of oral or intramuscular iodized oil with oral potassium iodide. A controlled trial in Zaire.

A community-based controlled trial of iodine supplementation comparing oral or intramuscular iodized oil with oral potassium iodide has been carried out in 23 severely iodine-deficient villages in Eastern Zaire. The overall goitre prevalence in the population (n = 5999) was 61% and mean urinary iodine excretion in sample of 57 women 10.9 (SD 6.8) micrograms/g creatinine. All adults in three groups of four villages were given single doses of potassium iodide of 0.5 g, 1.0 g, and 2.0 g respectively. A fourth group was given oral iodized oil (2 ml) and a fifth placebo-treated. A further three villages were given intramuscular iodized oil (2 ml). The effectiveness of supplementation was assessed by measurements of bloodspot thyroxine (T4) concentration in women of reproductive age in the villages. The effects of iodide were small and inconsistent. Eight months after supplementation with oral iodized oil the distribution of T4 concentrations was similar to that seen with intramuscular oil. We conclude that oral iodized oil is an effective alternative to injected oil and would be feasible for iodine supplementation in remote areas with untrained people.

Administration, Oral↗

PubMed2004

Sporotrichosis successfully treated with terbinafine and potassium iodide: case report and review of the literature.

Sporotrichosis is rare in Turkey. We report a 40-year-old woman who had subcutaneous sporotrichosis caused by sporothrix schenckii that was successfully treated with terbinafine (250 mg, twice a day) for a period of 6 months. She received a saturated solution of potassium iodide orally for two months. Terbinafine and potassium iodide are suggested to be the agents of choice for treatment of subcutaneous sporotrichosis.

Adult↗

PubMedDate not supplied

Enhancing nuclear emergency preparedness: Vermont's distribution program for potassium iodide.

On January 31, 2002, Vermont's health commissioner requested potassium iodide (KI) for individuals in the 10-mile Emergency Planning Zone of the nuclear power facility. Vermont's KI distribution program emphasized public information about the role, risks, and benefits of KI. Predistribution ensured that individuals could receive KI in a 0- to 4-hour time period, to provide maximum protection. Five months after the program began, more than 1,000 individuals had received KI, and 3,000-4,000 KI doses have been distributed in schools. Efforts are ongoing to identify barriers to participation, provide public education, and evaluate KI distribution efforts.

Community Participation↗

PubMed1989

Potassium iodide as a thyroid blocker--Three Mile Island to today.

The Three Mile Island (TMI) nuclear emergency in the U.S. in March 1979 marked the first occasion when use of potassium iodide (KI) was considered for thyroid blocking of the population in the vicinity of a potentially serious release of fission products from a nuclear power reactor. In face of a demand that could not be satisfied by commercial supplies of low-dose KI drug products from the U.S. pharmaceutical industry, the Food and Drug Administration directed the manufacture and stockpiling of sufficient quantities of saturated solution of potassium iodide (SSKI) to provide protection for one million people in the event of a large-scale release of radioiodines. Although the drug was not used, the experience of producing, stockpiling, and making ready for use a large quantity of the drug resulted in significant public policy, regulatory, and logistical issues. A number of these issues have been resolved through scientific debate and consensus, development of official guidance regarding the proper role of KI in nuclear emergencies, and the approval of New Drug Applications for KI products specifically intended for thyroid blocking in nuclear emergencies. Other issues regarding broad-scale implementation of the guidelines remain today. This paper traces the history of the development and implementation of the use of KI from pre-TMI to the present.

Accidents, Occupational↗

PubMedDate not supplied

Rapid microchemical identification of four phenothiazine antiemetics with gold bromide and iodine-potassium iodide reagents: collaborative study.

A microchemical method was developed for the rapid identification of 4 phenothiazine antiemetics. Perphenazine, promethazine, thiethylperazine, and triflupromazine were positively identified and differentiated with the aid of a gold bromide reagent and an iodine-potassium iodide reagent. Only promethazine and triflupromazine yielded microcrystalline derivatives with gold bromide; only perphenazine and thiethylperazine reacted with iodine-potassium iodide. For each pair of positive reactions, the crystalline products were morphologically distinguishable under a microscope. The 2 tests were collaboratively studied by 7 independent laboratories and found to be simple, rapid, and effective for identifying the phenothiazines of interest. The method has been adopted official first action.

Antiemetics↗

PubMed1981

Potassium iodide in the treatment of erythema nodosum and nodular vasculitis.

Twenty-nine patients with erythema nodosum, nodular vasculitis, or erythema nodosum-like lesions associated with Behçet's syndrome were treated with potassium iodide. Administration of the drug for systemic effect showed a substantial effect in 11 of 15 patients with erythema nodosum, seven of ten with nodular vasculitis, and one of four with leg lesions of Behçet's syndrome. Relief of subjective symptoms, including tenderness, joint pain, and fever, occurred within 24 hours. Substantial improvement in the eruption occurred within a few days, and the lesions disappeared completely ten to 14 days after therapy was initiated. The patients to whom the medication was administered shortly after the initial onset of erythema nodosum seemed to respond most satisfactorily. The effect of the drug was marked in the patients with positive C-reactive protein reactions, joint pains, and/or fever. Possible mechanisms by which potassium iodide exerts its effect are discussed.

Adult↗

PubMed1982

Control of severe thyrotoxicosis with potassium iodide and propranolol.

Conventional preparation of thyrotoxic patients for surgery using thiouracils and iodides may not be possible because of either, inability to obtain satisfactory therapeutic levels of the drugs or idiosyncratic reactions to the drugs. An alterative regime using potassium iodide and propranolol in combination has previously been shown to be both safe and effective in the pre-operative control of mild to moderate thyrotoxicosis. The use of this combination in a patient with severe thyrotoxicosis is described. Potassium iodide and propranolol can be used successfully to prepare patients with all degrees of thyrotoxicosis for surgery.

Adult↗

PubMed1985

[The uptake of potassium iodide and its effect as an antioxidant in isolated rabbit eyes].

Potassium iodide (KI) passes the cornea of isolated rabbit eyes with kinetics of approximately 0.25 mumol/h/ml aqueous humor. In photodynamic reactions, simulated as light-dependent decay of S-methyl-alpha-ketobutyric acid in the presence of riboflavin, KI acts as an antioxidant cooperating with internal scavengers such as ascorbate. With the simple model reactions applied it may be possible to study mechanism and functions in vivo of eye-protecting factors or combinations of compounds.

Animals↗

PubMed1990

[Leukocyte phagocytic activity in gerbils with experimental sporotrichosis treated with potassium iodide].

One effective treatment against sporotrichosis is the oral administration of potassium iodide (KI). It is not known how it works, and also it is not known if this substance has some effect on the microbicidal activity of polymorphonuclear neutrophils (PMN) and macrophages. In this work the phagocytic activity of gerbils treated with KI was studied. Gerbils cured within 62 days of treatment with KI, their PMN and macrophages showed an increased ability for reducing nitroblue-tetrazolium (NBT); myeloperoxidase activity was decreased in PMN. These results were the expected in any chronic infection and demonstrates that KI effectiveness on the experimental sporotrichosis works by an independent mechanism of phagocytosis.

Animals↗